Last quarter (Q3 2023), Vor Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Vor Biopharma's net income was $-33.19M. See Vor Biopharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 73.19M	$ 93.42M	$ 69.02M	$ 43.37M	$ 10.42M	$ 2.86M
Operating Income	$ -122.64M	$ -93.42M	$ -69.02M	$ -43.37M	$ -10.42M	$ -2.86M
Net Non Operating Interest Income Expense	$ 7.13M	$ 1.32M	$ 119.00K	$ 29.00K	$ -454.00K	$ -1.00M
Other Income Expense	-	-	-	-	$ 32.00K	$ -289.00K
Pretax Income	$ -115.51M	$ -92.09M	$ -68.90M	$ -43.34M	$ -10.84M	$ -4.15M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -115.51M	$ -92.09M	$ -70.13M	$ -49.26M	$ -12.61M	$ -4.15M
Basic EPS	$ -2.49	$ -2.33	$ -2.10	$ -1.42	$ -1.91	$ -0.73
Diluted EPS	$ -1.88	$ -2.33	$ -2.10	$ -1.42	$ -1.91	$ -0.73
Basic Average Shares	$ 240.46M	$ 39.55M	$ 33.43M	$ 34.64M	$ 5.66M	$ 5.66M
Diluted Average Shares	$ 240.46M	$ 39.55M	$ 33.43M	$ 34.64M	$ 5.66M	$ 5.66M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 73.19M	$ 93.42M	$ 69.02M	$ 43.37M	$ 10.42M	$ 2.86M
Net Income From Continuing And Discontinued Operation	$ -115.51M	$ -92.09M	$ -68.90M	$ -43.34M	$ -10.84M	$ -4.15M
Normalized Income	$ -49.90M	$ -72.75M	-	$ -43.34M	$ -10.87M	$ -3.86M
Interest Expense	-	-	-	$ 0.00	$ 608.00K	$ 1.00M
EBIT	$ -118.32M	$ -92.09M	$ -69.02M	$ -43.37M	$ -10.23M	$ -3.15M
EBITDA	$ -82.96M	$ -89.59M	$ -67.62M	$ -42.76M	$ -10.14M	$ -3.13M

Currency in USD

Vor Biopharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing